The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 2 under the chairmanship of Jean-Luc Belingard to approve the consolidated financial statements for the six months ended June 30, 2014. The Statutory Auditors had performed a limited review of the financial statements.
bioMérieux - First-Half 2014 Results
bioMérieux's TEMPO® (Bacillus Cereus) Assay Gains International Approval for Food Safety Testing
AOAC Research Institute validates performance of automated food safety solution
BioFire Diagnostics Initiates Clinical study for the FilmArray® Meningitis/Encephalitis Panel
Molecular test will quickly identify infectious causes of meningitis and encephalitis.
bioMérieux - Second-Quarter 2014 Business Review
Solid growth in first-half sales
bioMérieux Breaks Ground on New Production Line at Durham Facility
Expansion to help address the global public health threat of sepsis and meet the related demand for microbial detection.
bioMérieux 2013 Annual Report
In 2013, bioMérieux celebrated both its 50th anniversary and a remarkable entrepreneurial adventure at the service of public health worldwide.
bioMérieux Announces the Appointment of Stefan Willemsen as President and CEO of bioMérieux Inc.
bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the appointment of Stefan Willemsen as President and CEO of bioMérieux Inc.
The General Shareholders' Meeting of bioMérieux Approves the Appointment of Two New Independent Directors
The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent directors, Agnès Lemarchand and Philippe Gillet.
ASM 2014 - bioMérieux is Pioneering Diagnostics to Fight Antibiotic Resistance
Amid the growing global threat from antibiotic resistant organisms, bioMérieux is leveraging its robust history of fighting infectious diseases to provide solutions and services that aid Antibiotic Stewardship Programs.